Niacin for reduction of cardiovascular risk

Comment

Inge A M van den Oever et al. N Engl J Med. 2014.

. 2014 Nov 13;371(20):1942.

doi: 10.1056/NEJMc1411240.

No abstract available

Comment in

Niacin for reduction of cardiovascular risk.
Landray MJ, Haynes R, Armitage J. Landray MJ, et al. N Engl J Med. 2014 Nov 13;371(20):1943-4. doi: 10.1056/NEJMc1411240. N Engl J Med. 2014. PMID: 25390748 No abstract available.

Effects of extended-release niacin with laropiprant in high-risk patients.
HPS2-THRIVE Collaborative Group; Landray MJ, Haynes R, Hopewell JC, Parish S, Aung T, Tomson J, Wallendszus K, Craig M, Jiang L, Collins R, Armitage J. HPS2-THRIVE Collaborative Group, et al. N Engl J Med. 2014 Jul 17;371(3):203-12. doi: 10.1056/NEJMoa1300955. N Engl J Med. 2014. PMID: 25014686 Clinical Trial.
Niacin and HDL cholesterol--time to face facts.
Lloyd-Jones DM. Lloyd-Jones DM. N Engl J Med. 2014 Jul 17;371(3):271-3. doi: 10.1056/NEJMe1406410. N Engl J Med. 2014. PMID: 25014692 No abstract available.